Trials / Active Not Recruiting
Active Not RecruitingNCT03334500
Evaluating in Vivo PARP-1 Expression With 18F-FluorThanatrace Positron Emission Tomography (PET/CT) in Prostate Cancer
- Status
- Active Not Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Abramson Cancer Center at Penn Medicine · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Men with a history of prostate cancer may be in this study. Subjects recommended for a prostatectomy or oligometastectomy will undergo PET/CT imaging using a novel radiotracer \[18F\]FTT to evaluate PARP-1 activity in known or suspected sites of primary or metastatic disease. Imaging will be compared with pathology results, including additional research assays when possible.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | [18F]FluorThanatrace | Fluorine-18 labeled FluorThanatrace \[18F\]FTT can be synthesized with high specific activity so the quantity of mass injected with the radiopharmaceutical is \< 10 μg. |
| DRUG | Poly(ADP Ribose) Polymerase 1 | Poly(ADP-ribose) polymerase (PARP) is a family of enzymes involved in base excision repair (the repair of DNA single-strand breaks) and alternative end joining (repair of DNA double-strand breaks). The molecular basis of PARP1 inhibitor function may depend on the dual roles of PARP1 as a modulator of gene transcription in addition to DNA damage repair 3. |
Timeline
- Start date
- 2017-07-14
- Primary completion
- 2027-02-11
- Completion
- 2027-02-11
- First posted
- 2017-11-07
- Last updated
- 2026-02-20
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03334500. Inclusion in this directory is not an endorsement.